Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis
PaperCitations, authors & open-access status
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 260 citations, 2011 year and hybrid oa status.
260
Citations
2011
Year
hybrid
OA Status